Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback